Disclosures: Francisco Caballero-Camino: Nothing to Disclose, Irune Lasa: Nothing to Disclose, Ainhoa Lapitz: Nothing to Disclose, Xia Wu: CymaBay Therapeutics: Employee, Pedro Rodrigues: Nothing to Disclose, Noelia Pastor-Toyos: Nothing to Disclose, Laura Izquierdo-Sanchez: Nothing to Disclose, Jiangao Song: Nothing to Disclose, Edward Cable: CymaBay Therapetics: Employee, Jeffrey Johnson: CymaBay Therapeutics: Consultant, Yun-Jung Choi: Nothing to Disclose, Charles McWherter: Nothing to Disclose, Jesus Banales: Nothing to Disclose 2077 REGULATION OF HEPATIC MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 3/ATP-BINDING CASSETTE SUBFAMILY C MEMBER 3 (MRP3/ABCC3) BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR): A NOVEL MECHANISM TO REDUCE BILE ACID INJURY DURING CHOLESTASIS Colleen Hayes 1 Gina Gallucci 1 James Boyer 2 David Assis 2 Nisanne Ghonem 1 , 1 University of Rhode Island, 2 Yale School of Medicine, Liver Center Background: Cholestatic liver diseases are characterized by the accumulation of toxic bile acids
Labs often run small-scale studies to map how each parameter translates to full-scale
Abbreviations References 1
Many consumers are introduced to these products after they are marketed as a natural alternative for energy, pain relief, mood support, or assistance with opioid addiction and other substance-related conditions
Including its partnership with Augusta Universitys Medical College of Georgia (MCG) at Wellstar MCG Health, Wellstar will now operate seven teaching hospitals in the state
How much weight loss can I expect from semaglutide or tirzepatide alone
